title: Monoclonal antibodies and immunoconjugates in acute myeloid leukemia.
abstract: The use of monoclonal antibodies for patients with acute myeloid leukemia is based on targeting cell-surface antigens preferentially expressed on leukemic blasts while sparing normal cells and tissues. The majority of studies performed to date have used antibodies reactive with the CD33 antigen. Phase II studies have demonstrated antileukemic responses with all agents, although less so with unlabeled antibodies. The most promising results have been obtained in the treatment of minimal residual disease in patients with acute promyelocytc leukemia. Antibody-targeted chemotherapy with gemtuzumab ozogamicin has also shown significant activity in patients with relapsed acute myeloid leukemia. Radioimmunotherapy with beta-particle emitters may be most effective for the treatment of bulky disease or as part of a conditioning regimen for hematopoietic stem-cell transplantation, whereas radioimmunotherapy with alpha-particle emitters may be better suited to the treatment of small-volume or minimal residual leukemia. Whether or not monoclonal antibody therapy will improve disease outcome compared with conventional treatment regimens remains to be demonstrated by well-designed clinical trials.
authors.affiliation: Department of Hematology, Tor Vergata University Hospital, Viale Oxford 81, 00133 Rome, Italy. sergio.amadori@ptvonline.it
authors.forename: Sergio
authors.initials: S
authors.lastname: Amadori
authors.forename: Roberto
authors.initials: R
authors.lastname: Stasi
mesh_terms: D000208:Acute Disease; D000617:Aminoglycosides / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000954:Antigens, Surface / Q000187:drug effects / Q000276:immunology; D017326:Clinical Trials, Phase III as Topic; D000079982:Gemtuzumab; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use*; D007951:Leukemia, Myeloid / Q000188:drug therapy* / Q000276:immunology; D016896:Treatment Outcome
chemical_list: D000617:Aminoglycosides; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000954:Antigens, Surface; D018796:Immunoconjugates; D000079982:Gemtuzumab